Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)

Clinical trial NCT02503202 · COMPLETED

Trial details

NCT number: NCT02503202
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Prevention of Ebola Infection

Start date: 2015-08-17
Primary completion: 2016-05-02
Enrollment: 1197

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.